Lai Wang
Chief Tech/Sci/R&D Officer presso BEIGENE, LTD.
Patrimonio netto: 20 M $ in data 31/03/2024
Profilo
Il signor Lai Wang è un responsabile globale della ricerca e dello sviluppo di BeiGene Ltd.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
BEIGENE LTD
0.13% | 26/06/2023 | 1 658 215 ( 0.13% ) | 20 M $ | 31/03/2024 |
Posizioni attive di Lai Wang
| Società | Posizione | Inizio |
|---|---|---|
| BEIGENE, LTD. | Chief Tech/Sci/R&D Officer | 01/04/2021 |
Precedenti posizioni note di Lai Wang
| Società | Posizione | Fine |
|---|---|---|
Joyant Pharmaceuticals, Inc.
 Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Corporate Officer/Principal | - |
Formazione di Lai Wang
| Fudan University | Undergraduate Degree |
| University of Texas Health Science Center at Houston | Doctorate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| BEIGENE, LTD. | Health Technology |
| Aziende private | 1 |
|---|---|
Joyant Pharmaceuticals, Inc.
Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Health Technology |
- Borsa valori
- Insiders
- Lai Wang
